{
  "date_blocked": null, 
  "citation": {
    "state_cite_three": null, 
    "federal_cite_one": "510 U.S. 801", 
    "federal_cite_two": null, 
    "specialty_cite_one": null, 
    "federal_cite_three": null, 
    "lexis_cite": "", 
    "document_uris": [
      "/api/rest/v2/document/112941/"
    ], 
    "scotus_early_cite": null, 
    "case_name": "Rincon v. United States", 
    "westlaw_cite": null, 
    "state_cite_one": null, 
    "neutral_cite": null, 
    "state_cite_regional": null, 
    "state_cite_two": null, 
    "docket_number": "92-8439", 
    "id": 97300, 
    "resource_uri": "/api/rest/v2/citation/97300/"
  }, 
  "id": 112941, 
  "blocked": false, 
  "judges": "", 
  "court": "/api/rest/v2/jurisdiction/scotus/", 
  "date_filed": "1993-10-04", 
  "download_url": "http://bulk.resource.org/courts.gov/c/US/510/510.US.801.92-8439.html", 
  "source": "R", 
  "local_path": null, 
  "html_lawbox": "", 
  "time_retrieved": "2010-04-28T10:18:57", 
  "nature_of_suit": "", 
  "plain_text": "", 
  "html_with_citations": "<p class=\"case_cite\"><span class=\"citation no-link\"><span class=\"volume\">510</span> <span class=\"reporter\">U.S.</span> <span class=\"page\">801</span></span></p>\n    <p class=\"parties\">Rincon<br>v.<br>United States.</p>\n    <p class=\"docket\">No. 92-8439.</p>\n    <p class=\"court\">Supreme Court of United States.</p>\n    <p class=\"date\">October 4, 1993.</p>\n    <div class=\"num\" id=\"p1\">\n      <span class=\"num\">1</span>\n      <p class=\"indent\">Appeal from the C. A. 9th Cir.</p>\n    </div>\n    <div class=\"num\" id=\"p2\">\n      <span class=\"num\">2</span>\n      <p class=\"indent\">Motion of petitioner for leave to proceed <i>in forma pauperis</i> granted. Certiorari granted, judgment vacated, and case remanded for further consideration in light of <i>Daubert</i> v. <i>Merrell Dow Pharmaceuticals, Inc.,</i> 509 U. S. 579 (1993). Reported below: 984 F. 2d 1003.</p>\n    </div>\n    ", 
  "sha1": "550ca9ac67b22ed15ec8b469a561fc62ef8ed2ba", 
  "date_modified": "2014-12-21T02:13:21.261196", 
  "precedential_status": "Published", 
  "absolute_url": "/opinion/112941/rincon-v-united-states/", 
  "citation_count": 3, 
  "supreme_court_db_id": null, 
  "extracted_by_ocr": false, 
  "docket": "/api/rest/v2/docket/1298572/", 
  "html": "<p class=\"case_cite\">510 U.S. 801</p>\n    <p class=\"parties\">Rincon<br>v.<br>United States.</p>\n    <p class=\"docket\">No. 92-8439.</p>\n    <p class=\"court\">Supreme Court of United States.</p>\n    <p class=\"date\">October 4, 1993.</p>\n    <div class=\"num\" id=\"p1\">\n      <span class=\"num\">1</span>\n      <p class=\"indent\">Appeal from the C. A. 9th Cir.</p>\n    </div>\n    <div class=\"num\" id=\"p2\">\n      <span class=\"num\">2</span>\n      <p class=\"indent\">Motion of petitioner for leave to proceed <i>in forma pauperis</i> granted. Certiorari granted, judgment vacated, and case remanded for further consideration in light of <i>Daubert</i> v. <i>Merrell Dow Pharmaceuticals, Inc.,</i> 509 U. S. 579 (1993). Reported below: 984 F. 2d 1003.</p>\n    </div>\n    ", 
  "resource_uri": "/api/rest/v2/document/112941/"
}